A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults With Moderate-to-severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Tralokinumab (Primary) ; DTaP vaccine; Meningococcal vaccine conjugate
- Indications Atopic dermatitis
- Focus Pharmacodynamics
- Acronyms ECZTRA 5
- Sponsors LEO Pharma
- 08 Nov 2019 Planned End Date changed from 10 Oct 2019 to 10 Dec 2019.
- 22 May 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2018 Status changed from not yet recruiting to recruiting.